Form 4: Zevra Therapeutics CEO Neil McFarlane Awarded Stock Options and Restricted Stock Units

Neil F. McFarlane, CEO of Zevra Therapeutics, received stock options for 225,000 shares and 112,500 restricted stock units on February 7, 2025.

Summary

• Neil F. McFarlane, the President and CEO of Zevra Therapeutics, was granted stock options and restricted stock units on February 7, 2025.
• The stock options are for 225,000 shares with an exercise price of $7.77 per share.
• These options vest in four equal annual installments starting February 7, 2026, contingent upon continued service.
• Full vesting occurs upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason.
• The options expire on February 6, 2035.
• McFarlane also received 112,500 restricted stock units (RSUs), each representing a contingent right to receive one share of Zevra Therapeutics common stock.
• One third of the RSUs will vest on February 7, 2026, with the remaining two thirds vesting in equal annual installments thereafter, subject to continued service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of equity compensation is a standard practice and signals confidence in the CEO's ability to lead the company. However, it also represents potential dilution for existing shareholders.

Positives

• The grant of stock options and RSUs aligns the CEO's interests with those of the shareholders, incentivizing him to increase the company's value.
• The vesting schedule encourages long-term commitment from the CEO.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the equity grants.

Industry Context

Equity compensation is a common practice in the pharmaceutical industry to attract and retain top executive talent and align their interests with those of shareholders. The vesting schedule is typical for such grants.

Comparison to Industry Standards

• Stock option grants to CEOs in the pharmaceutical industry are common, with vesting schedules typically ranging from three to five years.
• The size of the grant is dependent on the company's market capitalization, the CEO's experience, and overall compensation strategy.
• Comparable companies such as BioCryst Pharmaceuticals and Catalyst Pharmaceuticals also utilize stock options and restricted stock units as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may experience dilution as the stock options and RSUs are exercised or vest.
• Employees may view the CEO's equity compensation as a positive sign of the company's commitment to leadership.

Key Dates

Keywords

ZEVRA THERAPEUTICS, Neil McFarlane, stock options, restricted stock units, equity compensation, Form 4, ZVRA